Skip to main content

Table 1 Characteristics of the study population

From: Analyzing the value of an educational program for psoriasis patients: a prospective controlled pilot study

CategoryNo. (%)p-value
t (n = 53)c (n = 29)i (n = 24)
Gender
 Female n (%)19 (35.8)12 (41.4)7 (29.2)0,40a
 Male n (%)34 (64.2)17 (58.6)17 (70.8)
Age
 Mean (SD)46.51 (12.0)46.93 (12.7)46.0 (11.4)0,78b
 Median (25%; 75%)48.0 (37.5; 56.0)48.0 (40.5; 57.5)48.5 (36.5; 54.0)
Self-reported BSA
 Mean (SD)8.56 (17.56)10.25 (20.27)6.67 (14.1)0,83c
 Median (25%; 75%)2.5 (1.0; 5.0)2.0 (0.3; 9.0)2.8 (1.3; 5.0)
DLQI
 Mean (SD)6.38 (6.93)6.28 (7.58)6.50 (6.22)0,55c
 Median (25%; 75%)4.0 (1.0; 9.0)4.0 (1.0; 7.5)5.0 (1.25; 10.0)
Disease duration
 Mean (SD)18.13 (12.76)19.29 (12.38)16.79 (13.34)0,49b
 Median (25%; 75%)15.0 (9.0; 26.5)18.0 (9.0; 27.0)12.0 (7.5; 20.0)
BMI
 Mean (SD)29.05 (6.27)28.32 (6.54)29.92 (5.95)0,10c
 Median (25%; 75%)27.4 (24.5; 32.1)25.3 (23.8; 32.4)28.4 (26.1; 32.5)
Comorbidity
 Psoriatic arthritis, n (%)18 (34)10 (34.5)8 (33.3)1,00a
 Depression, n (%)11 (21.2)7 (24.1)4 (17.4)0,73a
 Allergy, n (%)17 (32.7)11 (37.9)6 (26.1)0,39a
 Hypertension n (%)19 (36.5)10 (34.5)9 (39.1)0,78a
 Cardiovascular diseases, n (%)3 (5.8)2 (6.9)1 (5.5)1,00a
 Hypercholesterolemia, n (%)11 (21.2)5 (17.2)6 (26.1)0,51a
 COPD, asthma, n (%)9 (17.3)7 (24.1)2 (8.7)0,27a
 Hepatitis, cirrhosis of the liver, other liver diseases, n (%)3 (5.8)3 (10.3)00,25a
 Diabetes mellitus, n (%)5 (9.6)2 (6.9)3 (13)0,64a
 Cancer, n (%)1 (1.9)01 (5.5)0,44a
 No comorbidities, n (%)14 (26.9)8 (27.6)6 (26.1)1,00a
 Current smoker, n (%)20 (39.2)11 (39.3)9 (39.1)1,00a
 Ex-smoker, n (%)16 (31.4)7 (25)9 (39.1)0,37a
 Non-smoker, n (%)15 (29.4)10 (35.7)5 (21.7)0,36a
  1. aFisher’s exact test; bunpaired t-test; cMann-Whitney test; BMI Body-Mass-Index, BSA Body Surface Area (range: 0–100), c control, COPD Chronic obstructive pulmonary disease, DLQI Dermatology Life Quality Index, i intervention, n number, SD standard deviation, t total, 25% 25th percentile, 75% 75th percentile